Literature DB >> 26565993

Suppression of fructose-bisphosphate aldolase C expression as a predictor of advanced oral squamous cell carcinoma.

Yue-Ju Li1,2, Tse-Hung Huang3, Michael Hsiao4, Been-Ren Lin5, Shih-Jung Cheng6, Cheng-Ning Yang1,2,7, Wei-Ting Lai1, Tai-Sheng Wu1, Jia-Ruei Fan3, Mark Yen-Ping Kuo1,3,6, Cheng-Chi Chang2,3,6.   

Abstract

BACKGROUND: Glycolysis machinery regulates cancer cell behavior. However, the roles of these glycolysis enzymes in oral squamous cell carcinoma (OSCC) progression remain unknown.
METHODS: Fructose-bisphosphate aldolase C (ALDOC) expression in OSCC patients and cell lines was detected using quantitative real-time polymerase chain reaction (PCR). The functions of ALDOC in migration and invasion were determined using gain and loss of function approaches. An orthotopic OSCC animal model was performed to investigate the effects of ALDOC on metastasis and tumorigenesis in vivo.
RESULTS: ALDOC expression is negatively significantly correlated with clinical outcome and cell migration in vitro and in vivo. ALDOC blocks adenosine triphosphate generation and lactate production, and mutation constructs of Arg42 and Lys146 functionally restore ALDOC-inhibited cell migration and invasion.
CONCLUSION: ALDOC functions as an OSCC prognosis marker clinically, and suppresses migration and invasion by its catalytic domain of Arg42 and Lys146.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E1075-E1085, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  aldolase C (ALDOC); glycolysis; metabolism; metastasis; oral cancer

Mesh:

Substances:

Year:  2015        PMID: 26565993     DOI: 10.1002/hed.24161

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Downregulation of ALDOB is associated with poor prognosis of patients with gastric cancer.

Authors:  Jun He; Yi Jin; Yuan Chen; Hai-Bo Yao; Ying-Jie Xia; Ying-Yu Ma; Wei Wang; Qin-Shu Shao
Journal:  Onco Targets Ther       Date:  2016-10-07       Impact factor: 4.147

2.  Network of clinically-relevant lncRNAs-mRNAs associated with prognosis of hepatocellular carcinoma patients.

Authors:  Lee Jin Lim; Yu Jin; Henry Yang; Alexander Y F Chung; Brian K P Goh; Pierce K H Chow; Chung Yip Chan; William K Blanks; Peng Chung Cheow; Ser Yee Lee; Tony K H Lim; Samuel S Chong; London L P J Ooi; Caroline G Lee
Journal:  Sci Rep       Date:  2020-07-07       Impact factor: 4.379

3.  Enrichment of Aldolase C Correlates with Low Non-Mutated IDH1 Expression and Predicts a Favorable Prognosis in Glioblastomas.

Authors:  Yu-Chan Chang; Hsing-Fang Tsai; Shang-Pen Huang; Chi-Long Chen; Michael Hsiao; Wen-Chiuan Tsai
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

4.  Glycolytic pathway candidate markers in the prognosis of oral squamous cell carcinoma: a systematic review with meta-analysis.

Authors:  S E C de Mattos; L F Diel; L S Bittencourt; C E Schnorr; F A Gonçalves; L Bernardi; M L Lamers
Journal:  Braz J Med Biol Res       Date:  2021-01-25       Impact factor: 2.590

5.  The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells - a case of inter-tumor heterogeneity.

Authors:  Sivan Izraely; Shlomit Ben-Menachem; Orit Sagi-Assif; Tsipi Meshel; Sapir Malka; Alona Telerman; Matias A Bustos; Romela Irene Ramos; Metsada Pasmanik-Chor; Dave S B Hoon; Isaac P Witz
Journal:  Mol Oncol       Date:  2020-12-14       Impact factor: 6.603

6.  A prognostic Risk Score model for oral squamous cell carcinoma constructed by 6 glycolysis-immune-related genes.

Authors:  Yi Liu; Tong Wang; Ronghua Li
Journal:  BMC Oral Health       Date:  2022-08-03       Impact factor: 3.747

7.  Identification of a gene expression signature associated with the metastasis suppressor function of NME1: prognostic value in human melanoma.

Authors:  M Kathryn Leonard; Joseph R McCorkle; Devin E Snyder; Marian Novak; Qingbei Zhang; Amol C Shetty; Anup A Mahurkar; David M Kaetzel
Journal:  Lab Invest       Date:  2017-10-23       Impact factor: 5.662

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.